{"title":"Xpert MTB/RIF Ultra as a diagnostic tool for pleural tuberculosis: a study at Indian tertiary care centre.","authors":"Sumedha Sharma, Prabhdeep Kaur, Ashutosh N Aggarwal, Khushpreet Kaur, Rakesh Yadav, Sunil Sethi, Indu Verma","doi":"10.1093/lambio/ovae102","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the advent of Xpert MTB/RIF, pleural tuberculosis (TB) diagnosis in pleural fluid is still difficult. Hence, we assessed the diagnostic efficacy of its advanced version, Xpert MTB/RIF Ultra for pleural TB diagnosis using pleural fluid as sample. Tuberculosis pleuritis (TBP) suspects (n = 261) were enrolled in the study of which 29 were excluded. The remaining patients (n = 232) were categorized into definite TBP (n = 31), probable TBP (n = 28), and non-TB controls (n = 173) based on composite reference standard consisting of smear, culture, histopathology, and Xpert MTB/RIF as well as follow up/clinical response to anti-tuberculosis therapy. Among the TBP suspects, 59 were diagnosed as TBP patients. The sensitivity of Xpert MTB/RIF Ultra (52.5%) using pleural fluid for TBP diagnosis was higher than sensitivity obtained with smear (22.4%), culture (17.6%), and Xpert MTB/RIF (25%) alone, carried using either pleural fluid or pleural biopsy or both the samples. In cases of probable TBP, where none of the laboratory tests were positive, Xpert MTB/RIF Ultra use led to an increased diagnostic percentage of definite TBP from 52.5% to 69.4% Overall, the Xpert MTB/RIF Ultra showed promising results for a definitive diagnosis of TBP in pleural fluid samples.</p>","PeriodicalId":17962,"journal":{"name":"Letters in Applied Microbiology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Letters in Applied Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1093/lambio/ovae102","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Despite the advent of Xpert MTB/RIF, pleural tuberculosis (TB) diagnosis in pleural fluid is still difficult. Hence, we assessed the diagnostic efficacy of its advanced version, Xpert MTB/RIF Ultra for pleural TB diagnosis using pleural fluid as sample. Tuberculosis pleuritis (TBP) suspects (n = 261) were enrolled in the study of which 29 were excluded. The remaining patients (n = 232) were categorized into definite TBP (n = 31), probable TBP (n = 28), and non-TB controls (n = 173) based on composite reference standard consisting of smear, culture, histopathology, and Xpert MTB/RIF as well as follow up/clinical response to anti-tuberculosis therapy. Among the TBP suspects, 59 were diagnosed as TBP patients. The sensitivity of Xpert MTB/RIF Ultra (52.5%) using pleural fluid for TBP diagnosis was higher than sensitivity obtained with smear (22.4%), culture (17.6%), and Xpert MTB/RIF (25%) alone, carried using either pleural fluid or pleural biopsy or both the samples. In cases of probable TBP, where none of the laboratory tests were positive, Xpert MTB/RIF Ultra use led to an increased diagnostic percentage of definite TBP from 52.5% to 69.4% Overall, the Xpert MTB/RIF Ultra showed promising results for a definitive diagnosis of TBP in pleural fluid samples.
期刊介绍:
Journal of & Letters in Applied Microbiology are two of the flagship research journals of the Society for Applied Microbiology (SfAM). For more than 75 years they have been publishing top quality research and reviews in the broad field of applied microbiology. The journals are provided to all SfAM members as well as having a global online readership totalling more than 500,000 downloads per year in more than 200 countries. Submitting authors can expect fast decision and publication times, averaging 33 days to first decision and 34 days from acceptance to online publication. There are no page charges.